Stryker Corporation key statistics and ratios
In fiscal 2025, Stryker Corporation had return on equity of 15.1%, an operating margin of 19.5%, debt equal to 70.7% of equity and a current ratio of 1.89. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 67.5% | 68.8% | 66.2% | 67.9% | 66.7% | 65.7% | 66.4% | 66.3% | 65.7% | 65.7% | 65.1% | 63.1% | 64.1% | 62.8% | 63.7% | 63.9% | 64.0% | 65.3% |
| Operating margin | 23.7% | 23.9% | 20.3% | 20.1% | 13.9% | 12.9% | 18.7% | 19.2% | 18.5% | 18.7% | 18.2% | 15.5% | 15.1% | 15.4% | 19.0% | 16.3% | 19.5% | 20.7% |
| Net margin | 16.5% | 17.4% | 16.2% | 15.0% | 11.2% | 5.3% | 14.5% | 14.5% | 8.2% | 26.1% | 14.0% | 11.1% | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% | 13.8% |
| Free-cash-flow margin | 19.8% | 18.6% | 14.5% | 16.7% | 18.7% | 16.0% | 7.1% | 12.6% | 7.7% | 15.0% | 10.4% | 19.4% | 16.0% | 11.0% | 15.3% | 15.4% | 17.1% | 17.4% |
| Return on equity | 16.8% | 18.5% | 18.1% | 15.9% | 11.4% | 5.8% | 16.8% | 18.2% | 10.5% | 32.8% | 17.0% | 12.4% | 14.3% | 15.0% | 18.0% | 15.3% | 15.1% | 15.8% |
| Return on assets | 12.2% | 12.9% | 11.8% | 10.2% | 7.0% | 3.2% | 8.6% | 9.0% | 4.8% | 14.4% | 7.3% | 5.0% | 5.8% | 6.6% | 8.2% | 7.2% | 7.1% | 7.6% |
| Asset turnover | 0.74 | 0.74 | 0.73 | 0.68 | 0.63 | 0.59 | 0.59 | 0.62 | 0.58 | 0.55 | 0.52 | 0.45 | 0.50 | 0.52 | 0.53 | 0.55 | 0.55 | 0.55 |
| Current ratio | 4.06 | 4.76 | 3.92 | 4.34 | 3.14 | 1.95 | 2.27 | 2.50 | 2.29 | 2.02 | 2.51 | 1.93 | 2.20 | 1.63 | 1.58 | 1.95 | 1.89 | 2.18 |
| Debt to equity | 0.3% | 14.2% | 29.5% | 20.5% | 30.6% | 46.2% | 47.0% | 72.4% | 72.5% | 84.0% | 86.6% | 106.9% | 83.9% | 78.5% | 69.9% | 65.9% | 70.7% | 63.6% |
| Interest cover (operating income ÷ interest) | 113.9x | 33.0x | 30.1x | 27.6x | 15.1x | 11.0x | 17.2x | 9.5x | 9.3x | 9.6x | 9.5x | 7.1x | 7.7x | 8.4x | 10.7x | 9.0x | 8.1x | 9.3x |
| Effective tax rate | 31.8% | 26.4% | 20.2% | 23.9% | 17.0% | 55.6% | 17.1% | 14.3% | 50.6% | — | 18.7% | 18.2% | 12.6% | 12.1% | 13.8% | 14.3% | 28.1% | 29.2% |
| R&D as % of revenue | 5.0% | 5.4% | 5.6% | 5.4% | 5.9% | 6.3% | 6.3% | 6.3% | 6.3% | 6.3% | 6.5% | 6.9% | 7.2% | 7.9% | 6.8% | 6.5% | 6.5% | 6.4% |
| SG&A as % of revenue | 37.3% | 37.0% | 37.9% | 38.9% | 38.4% | 36.7% | 36.3% | 36.5% | 36.6% | 37.5% | 36.0% | 37.4% | 37.6% | 34.6% | 34.7% | 34.0% | 34.4% | 34.4% |
| Capital spending as % of revenue | 1.9% | 2.5% | 2.7% | 2.4% | 2.2% | 2.4% | 2.7% | 4.3% | 4.8% | 4.2% | 4.4% | 3.4% | 3.1% | 3.2% | 2.8% | 3.3% | 3.0% | 3.3% |
| Free cash flow ÷ net income | 120.1% | 107.2% | 89.8% | 111.5% | 168.1% | 300.8% | 49.4% | 86.5% | 94.2% | 57.4% | 74.0% | 174.5% | 137.3% | 86.3% | 99.1% | 116.5% | 131.9% | 126.2% |
| Dividends ÷ net income | 17.9% | 18.7% | 20.7% | 25.0% | 39.9% | 89.7% | 36.2% | 34.5% | 62.4% | 19.8% | 37.4% | 54.0% | 47.6% | 44.6% | 36.0% | 40.7% | 39.6% | 36.8% |
| Dividends and buybacks ÷ free cash flow | 14.9% | 48.6% | 74.6% | 29.9% | 42.5% | 36.3% | 171.7% | 40.8% | 90.1% | 49.2% | 70.4% | 30.9% | 34.7% | 51.6% | 36.3% | 35.0% | 30.0% | 29.1% |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 64.9% | 63.8% | 63.8% | 63.6% | 64.5% | 63.3% | 68.3% | 65.2% |
| Operating margin | 9.0% | 14.3% | 18.5% | 18.7% | 25.2% | 15.5% | 25.2% | 15.9% |
| Net margin | 8.5% | 11.1% | 14.7% | 14.2% | 11.8% | 12.4% | 19.4% | 11.5% |
| Free-cash-flow margin | 25.9% | 2.2% | 15.4% | 22.3% | 26.1% | 6.9% | 16.1% | 18.8% |
| Current ratio | 1.95 | 1.64 | 1.78 | 1.85 | 1.89 | 2.11 | 2.16 | 2.18 |
| Debt to equity | 65.9% | 80.2% | 78.2% | 76.2% | 70.7% | 64.1% | 62.3% | 63.6% |
| R&D as % of revenue | 5.6% | 6.9% | 6.8% | 6.8% | 5.6% | 6.9% | 6.6% | 6.6% |
| SG&A as % of revenue | 33.0% | 39.2% | 34.5% | 33.8% | 31.1% | 37.9% | 33.8% | 35.5% |
Financial health
- Short-term assets cover short-term liabilities $14.2bn of assets due within a year against $6.5bn of liabilities due within a year.
- Short-term assets cover long-term liabilities $14.2bn short-term assets against $17.3bn of longer-dated liabilities.
- More cash than debt $3.3bn of cash against $14.9bn of debt.
- Debt below 40% of shareholders' equity Debt is 64% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 92% to 64% over five years.
- A year's operating cash flow covers at least 20% of debt $5.4bn of operating cash flow against $14.9bn of debt.
- Operating profit covers interest at least five times over Operating income of $5.4bn against $586m of interest.
Moat
Strong moat
How hard Stryker's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 10 / 20
Net income has been a median 6.8% of total assets over 10 years.
- Pricing power 20 / 20
Gross margin has been a median 63.9%, moving by 1.0 percentage points (standard deviation) across 10 years.
- Durability 15 / 20
Operating margin has been a median 17.2%; its worst year was 15.0%.
- Cash conversion 17 / 20
Free cash flow was positive in 10 of 10 years, at a median 13.8% of revenue.
- Discipline 16 / 20
The diluted share count rose 0.7% over five years; stock-based pay has been a median 1.0% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- GE HealthCare statistics
- Boston Scientific statistics
- Koninklijke Philips NV statistics
- Medtronic statistics
- Abbott Laboratories statistics
Head to head: GEHC vs SYKBSX vs SYKPHG vs SYKMDT vs SYK
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies